Page 28 - Solid Tumors News Today

-Record Net Product Sales of $544 Million in 2Q23, an Increase of 26% Over 2Q22, Contributing to Total Revenues of $604 Million in 2Q23- -Strong PADCEV® Growth Driven By Combination First-Line...

Los Angeles-based City of Hope researchers have developed a new chemotherapy pill that appears to kill all solid tumors.

JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and Drug Administration approval represents a...

JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and...

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy Patients with this type of endometrial cancer face...

31.07.2023 - GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult ...

-- Approval Based on Clinically Meaningful Overall Survival Benefit Demonstrated in the TROPiCS-02 Study in Pre-Treated HR+/HER2- Metastatic Breast Cancer vs. Physician’s Choice of Chemotherapy...

FOR IMMEDIATE RELEASE 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational...

2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of...

FRα expression is limited on normal cells, but upregulated in ovarian cancer cells.